Covetrus公司（纳斯达克股票代码：CVET）卖空更新

Covetrus, Inc. (NASDAQ:CVET – Get Rating) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 4,110,000 shares, a growth of 45.7% from the June 15th total of 2,820,000 shares. Based on an average daily volume of 2,030,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.9% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Covetrus from $18.00 to $16.00 and set a "sell" rating for the company in a research report on Thursday, May 19th. Barclays downgraded shares of Covetrus from an "overweight" rating to an "equal weight" rating and lowered their price target for the stock from $26.00 to $21.00 in a research note on Thursday, May 26th. Raymond James downgraded shares of Covetrus from an "outperform" rating to a "market perform" rating in a research note on Monday, May 23rd. Stifel Nicolaus downgraded shares of Covetrus from a "buy" rating to a "hold" rating and set a $22.00 price objective for the company. in a research note on Monday, June 13th. Finally, William Blair downgraded shares of Covetrus from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 25th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $22.67.

Get Covetrus alerts:

Covetrus Trading Down 0.1 %

Shares of CVET opened at $20.76 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.03 and a current ratio of 1.86. Covetrus has a fifty-two week low of $13.39 and a fifty-two week high of $25.95. The firm's 50-day simple moving average is $20.03 and its two-hundred day simple moving average is $17.93.

Covetrus (NASDAQ:CVET – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. Covetrus had a negative net margin of 0.87% and a positive return on equity of 1.92%. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $0.16 EPS. Sell-side analysts forecast that Covetrus will post 0.83 EPS for the current year.

Insider Buying and Selling

In related news, Director Edward Mcnamara sold 34,525 shares of Covetrus stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $20.52, for a total value of $708,453.00. Following the completion of the transaction, the director now directly owns 31,807 shares in the company, valued at approximately $652,679.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Benjamin Wolin sold 5,293 shares of the business's stock in a transaction on Tuesday, July 12th. The shares were sold at an average price of $20.75, for a total transaction of $109,829.75. Following the completion of the transaction, the chief executive officer now directly owns 198,238 shares in the company, valued at approximately $4,113,438.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward Mcnamara sold 34,525 shares of the business's stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $20.52, for a total transaction of $708,453.00. Following the transaction, the director now owns 31,807 shares of the company's stock, valued at $652,679.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,111 shares of company stock valued at $927,319. 0.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. grew its stake in Covetrus by 3.3% during the fourth quarter. American Century Companies Inc. now owns 460,840 shares of the company's stock valued at $9,203,000 after acquiring an additional 14,518 shares in the last quarter. Public Sector Pension Investment Board grew its stake in shares of Covetrus by 0.9% in the 4th quarter. Public Sector Pension Investment Board now owns 210,480 shares of the company's stock worth $4,203,000 after buying an additional 1,930 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Covetrus by 22.0% in the 4th quarter. Teacher Retirement System of Texas now owns 20,012 shares of the company's stock worth $400,000 after buying an additional 3,605 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Covetrus by 87.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,028,735 shares of the company's stock worth $20,544,000 after buying an additional 479,008 shares in the last quarter. Finally, GW&K Investment Management LLC grew its stake in shares of Covetrus by 3.2% in the 4th quarter. GW&K Investment Management LLC now owns 1,563,907 shares of the company's stock worth $31,231,000 after buying an additional 48,224 shares in the last quarter. 93.99% of the stock is currently owned by institutional investors.

Covetrus Company Profile

(Get Rating)

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.

Read More

• Get a free copy of the StockNews.com research report on Covetrus (CVET)
• Alibaba Group: A Huge Revenue Rebound Is Approaching
• Is There Finally Green Ahead for These 2 Cannabis Leaders?
• Ford Races Higher: Has The Stock Finally Bottomed?
• These Consumer Stocks Will Thrive And Here's Why
• PayPal Stock is Attempting to Put in the Floor

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.